MRCT Center Post-Trial Responsibilities Framework Continued Access to Investigational Medicines. Guidance Document. Version 1.0, December 2016

The Multi-Regional Clinical Trials Center of the Brigham and Women’s Hospital and Harvard (MRCT Center) (2016)
Download Edit this record How to cite View on PhilPapers
Abstract
I. EXECUTIVE SUMMARY The MRCT Center Post-trial Responsibilities: Continued Access to an Investigational Medicine Framework outlines a case-based, principled, stakeholder approach to evaluate and guide ethical responsibilities to provide continued access to an investigational medicine at the conclusion of a patient’s participation in a clinical trial. The Post-trial Responsibilities (PTR) Framework includes this Guidance Document as well as the accompanying Toolkit. A 41-member international multi-stakeholder Workgroup convened by the Multi-Regional Clinical Trials Center of Brigham and Women’s Hospital and Harvard University (MRCT Center) developed this Guidance and Toolkit. Project Motivation A number of international organizations have discussed the responsibilities stakeholders have to provide continued access to investigational medicines. The World Medical Association, for example, addressed post-trial access to medicines in Paragraph 34 of the Declaration of Helsinki (WMA, 2013): “In advance of a clinical trial, sponsors, researchers and host country governments should make provisions for post-trial access for all participants who still need an intervention identified as beneficial in the trial. This information must also be disclosed to participants during the informed consent process.” This paragraph and other international guidance documents converge on several consensus points: • Post-trial access (hereafter referred to as “continued access” in this Framework [for terminology clarification – see definitions]) is the responsibility of sponsors, researchers, and host country governments; • The plan for continued access should be determined before the trial begins, and before any individual gives their informed consent; • The protocol should delineate continued access plans; and • The plan should be transparent to potential participants and explained during the informed consent process. However, there is no guidance on how to fulfill these responsibilities (i.e., linking specific responsibilities with specific stakeholders, conditions, and duration). To fill this gap, the MRCT Center convened a working group in September of 2014 to develop a framework to guide stakeholders with identified responsibilities. This resultant Framework sets forth applicable principles, approaches, recommendations and ethical rationales for PTR regarding continued access to investigational medicines for research participants.
PhilPapers/Archive ID
CARMCP
Revision history
Archival date: 2016-12-12
View upload history
References found in this work BETA
An Ethical Framework for Biomedical Research.Emanuel, Ezekiel J.; Wendler, David & Grady, C.
Making Fair Choices on the Path to Universal Health Coverage.Norheim, Ole Frithjof; Ottersen, Trygve; Chitah, Bona; Cookson, Richard; Daniels, Norman; Eyal, Nir; Flores, Walter; Gosseries, Axel; Hausman, Daniel; Hurst, Samia; Kapiriri, Lydia; Ord, Toby; Segall, Shlomi; Defaye, Frehiwot; Voorhoeve, Alex & Yamin, Alicia

Add more references

Citations of this work BETA

No citations found.

Add more citations

Added to PP index
2016-12-12

Total views
249 ( #16,707 of 47,300 )

Recent downloads (6 months)
33 ( #23,619 of 47,300 )

How can I increase my downloads?

Downloads since first upload
This graph includes both downloads from PhilArchive and clicks to external links.